Unlocking Profit Potential: Axsome Therapeutics Unveils Promising Data and Analysis of Auvelity for Major Depressive Disorder at ACNP 2023 Annual Meeting
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a…